# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# B Applicant

Siemens Healthcare Diagnostics Inc.

C Proprietary and Established Names

ADVIA Centaur $\textsuperscript { \textregistered }$ Vitamin D Total (VitD)

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MRG</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1825 -Vitamin D Test System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

Modified device to reinstate plasma (sodium heparin, lithium heparin, $\mathrm { K } _ { 2 }$ EDTA, K3 EDTA) as a sample matrix.

B Measurand: 25-hydroxyvitamin D   
C Type of Test: Quantitative chemiluminescent

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The ADVIA Centaur $\textsuperscript { \textregistered }$ Vitamin D Total (VitD) assay is for in vitro diagnostic use in the quantitative determination of total 25(OH)vitamin D in human serum and plasma (EDTA, lithium heparin, sodium heparin) using ADVIA Centaur $\textsuperscript { \textregistered }$ analyzers. The ADVIA Centaur $\textsuperscript { \textregistered }$ VitD assay is intended as an aid in the determination of vitamin D sufficiency.

Rx - For Prescription Use Only

D Special Instrument Requirements:

ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer

# IV Device/System Characteristics:

# A Device Description:

The ADVIA Centaur $\textsuperscript { \textregistered }$ Vitamin D reagent kit comes in two configurations (100 or 500 test kit) and each kit contains the following:

ReadyPack $\textsuperscript { \textregistered }$ primary reagent pack containing ADVIA Centaur Vit D Lite Reagent, Solid Phase Reagent, and Ancillary Well Reagent ReadyPack $\textsuperscript { \textregistered }$ ancillary pack containing ADVIA Centaur Vit D Ancillary Reagent ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D Low Calibrator • ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D High Calibrator ADVIA Centaur $\textsuperscript { \textregistered }$ systems Vit D Master Curve card ADVIA Centaur $\textsuperscript { \textregistered }$ systems Vit D Calibrator Assigned Value Card

The Vit D Reagents consists of the following:

Lite Reagent 5.0 mL/reagent pack: The reagent contains anti-Vit D (monoclonal mouse) antibody labeled with acridinium ester $( \mathrm { { \sim } 0 . 8 \ \mu \mathrm { { g / m L } ) } }$ in buffer with bovine serum albumin, mouse IgG, and sodium azide $( < 0 . 1 \% )$

Solid Phase Reagent 10.0 mL/reagent pack:   
The Solid Phase Reagent contains anti-fluorescein (monoclonal mouse)-coated paramagnetic particles (PMP) $( \sim 0 . 6 0 \mathrm { m g / m L } )$ in buffer with bovine serum albumin, surfactant, and sodium azide $( < 0 . 1 \% )$

Ancillary Well Reagent 5.0 mL/reagent pack:

The Ancillary Well Reagent contains vitamin D-analog conjugated to fluorescein $( { \sim } 0 . 2 ~ \mu \mathrm { g / m L } )$ and 1-anilinonaphthalene-8-sulfonic acid in buffer with bovine serum albumin and sodium azide $( < 0 . 1 \% )$

Ancillary Reagent Pack 25.0 mL/reagent pack:   
The Ancillary Reagent Pack contains releasing agent in buffered saline with sodium azide   
$\left( < 0 . 1 \% \right)$ and stabilizers

Material Required but Not Provided ADVIA Centaur $\textsuperscript { \textregistered }$ Wash 1

Optional Materials

• ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D Quality Control Material • ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D Diluent • ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D Master Curve Material (MCM)

# B Principle of Operation:

The ADVIA Centaur $\textsuperscript { \textregistered }$ Vit D assay is an 18-minute antibody competitive immunoassay that uses an anti-fluorescein monoclonal mouse antibody covalently bound to paramagnetic particles (PMP), an anti-25(OH)vitamin D monoclonal mouse antibody labeled with acridinium ester (AE), and a vitamin D analog labeled with fluorescein.

An inverse relationship exists between the total amount of 25(OH) vitamin D present in the patient sample and the amount of relative light units (RLU) detected by the system.

# V Substantial Equivalence Information:

A Predicate Device Name(s): ADVIA Centaur $\textsuperscript { \textregistered }$ Vitamin D Total (VitD) Assay   
B Predicate 510(k) Number(s): K133156   
C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K200509</td><td colspan="1" rowspan="1">K133156</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">ADVIA Centaur®Vitamin D Total(Vit D) assay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">For the quantitativedetermination of total25(OH)vitamin D. Theassay is intended as anaid in the determinationof vitamin Dsufficiency.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">Competitiveimmunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection Antibody</td><td colspan="1" rowspan="1">Monoclonal mouseantibody labeled withacridium ester (AE)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antibody</td><td colspan="1" rowspan="1">Anti-fluorescein labeled(FITC) monoclonalmouse antibodycovalently bound toparamagnetic particles(PMP).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">4.2 to 150 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Ancillary Pack Reagent</td><td colspan="1" rowspan="1">Buffering agent (highmolarity) and enhancedreleasing agent (lowmolecular weight)</td><td colspan="1" rowspan="1">Buffering agent (lowmolarity) and releasingagent (high molecularweight)</td></tr></table>

# VI Standards/Guidance Documents Referenced:

• CLSI. EP17-A2, 2012 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition

• CLSI EP06-A, 2003 Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline – First Edition

• CLSI EP05-A3, 2014; Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline—Third Edition

• CLSI EP34, 2018; Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking – First Edition

• CLSI EP28-A3c – formerly C28-A3c, 2010; Defining, Establishing and Verifying

Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition

• CLSI EP25-A, 2009; Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline– First Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Within run and total imprecision were evaluated by analyzing six serum samples at the concentrations below. Each sample was assayed in 2 replicates per run, 2 runs per day for 20 days for a total of 80 replicates per sample. Testing was performed with one reagent lot on one ADVIA Centaur $^ \mathrm { \textregistered }$ XP analyzer. Results are summarized below:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>21.29</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.04</td><td rowspan=1 colspan=1>9.6</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>26.10</td><td rowspan=1 colspan=1>1.56</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>2.37</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>32.16</td><td rowspan=1 colspan=1>1.71</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>2.38</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>Serum 4</td><td rowspan=1 colspan=1>65.47</td><td rowspan=1 colspan=1>2.52</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>3.60</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>Serum 5</td><td rowspan=1 colspan=1>84.12</td><td rowspan=1 colspan=1>1.90</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.34</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Serum 6</td><td rowspan=1 colspan=1>132.32</td><td rowspan=1 colspan=1>3.13</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>4.76</td><td rowspan=1 colspan=1>3.6</td></tr></table>

2. Linearity:

This study was conducted following the guidelines of CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures.

A high $\mathrm { ( > 1 5 0 n g / m L ) }$ ) Vitamin D sample was made by spiking 25(OH) Vitamin D into a human serum sample. Vitamin D stripped human serum was used as the low sample. A dilution series was then made by mixing the high and low samples to encompass the measuring interval of the Vitamin D assay. Each resulting sample was run in triplicate on one reagent lot on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer.

The sponsor concluded that the modified assay is linear from $2 . 7 8 ~ \mathrm { n g / m L }$ to $1 5 1 . 0 0 \mathrm { n g / m L }$ on the ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer. A measuring range from $4 . 2 - 1 5 0 \mathrm { n g / m L }$ is claimed in the labeling.

# Dilution Recovery:

To validate the labeling instructions that patient samples with Vitamin D levels above the claimed measuring range can be manually or automatically diluted 1:2, 5 unique serum samples were spiked with 25(OH) Vitamin D to produce concentrations ranging from 186 - $2 1 1 \mathrm { \ n g / m L }$ . The samples were then diluted 1:2 with ADVIA Centaur $\textsuperscript { \textregistered }$ VitD diluent and assayed for recovery. The recoveries ranged from $9 7 \%$ to $109 \%$ .

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Observed(ng/mL)</td><td rowspan=1 colspan=1>Expected(ng/mL)</td><td rowspan=1 colspan=1>Recovery %</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1:2</td><td rowspan=1 colspan=1>96.0</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1:2</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>93.0</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1:2</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>103.5</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1:2</td><td rowspan=1 colspan=1>102.5</td><td rowspan=1 colspan=1>105.5</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1:2</td><td rowspan=1 colspan=1>102.1</td><td rowspan=1 colspan=1>93.5</td><td rowspan=1 colspan=1>109</td></tr></table>

3. Analytical Specificity/Interference:

Assay specificity was established during the review of k133156.

4. Assay Reportable Range:

The ADVIA Centaur $\textsuperscript { \textregistered }$ VitD assay measures 25(OH) vitamin D from concentrations of 4.2 to $1 5 0 ~ \mathrm { { n g / m L } }$ (10.5 to $3 7 5 \mathrm { n m o l / L }$ ). The claimed measuring range is defined by the limit of quantitation (LoQ), linearity, and method comparison studies.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The ADVIA Centaur $\textsuperscript { \textregistered }$ VitD calibrators are traceable to the NIST SRM972a 25-OH Vitamin D reference material.

6. Detection Limit:

A limit of blank (LoB) study was conducted following the guidelines of CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures. Four blank samples with no Vitamin D were run $\mathrm { n } { = } 6$ for 6 days, 2 runs/day on 2 reagent lots for a total $\mathrm { n } { = } 7 2$ reps per sample per lot, on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer. The LoB was calculated as $1 . 5 2 ~ \mathrm { { n g / m L } }$ .

A limit of detection (LoD) study was conducted following the guidelines of CLSI EP17-A2. Four (4) low level samples were made by diluting individual patient samples with Vitamin D stripped serum to concentrations around the expected LoD. Samples were run $\mathrm { n } { = } 6$ for 5 days, 2 runs per day on 2 reagent lots on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer for a total $\scriptstyle \mathrm { n = 6 0 }$ replicates per sample, and lot. The LoD was calculated as $3 . 1 1 ~ \mathrm { n g / m L }$ .

A limit of quantitation (LoQ) study was conducted following the guidelines of CLSI EP17- A2. Thirteen (13) unique native serum specimens were diluted with Vitamin D stripped serum to produce concentrations ranging from 1.24 to $2 5 . 6 \mathrm { n g / m L }$ , Samples were run $\mathrm { n } { = } 6$ for 5 days, 2 runs per day on two reagent lots, on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer for a total $\scriptstyle \mathrm { n = 6 0 }$ replicates per sample, lot, platform, across 5 days. Data was analyzed 2 point using a stored calibration. LoQ was calculated by precision profile and was defined as the concentration at which the within-lab coefficient of variation was $20 \%$ . The LoQ was calculated as $4 . 2 4 ~ \mathrm { n g / m L }$ .

These studies support the following labeling claims:

<table><tr><td rowspan=1 colspan=1>Limit of blank</td><td rowspan=1 colspan=1>1.7 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Limit of detection</td><td rowspan=1 colspan=1>3.2 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Limit of quantitation</td><td rowspan=1 colspan=1>4.2 ng/mL</td></tr></table>

7. Assay Cut-Off:

Not applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

To compare results from the modified device to the predicate, one hundred twenty-six (126) serum samples (including 118 native and 8 contrived) were run in singlicate over 2 days using two lots of modified reagent and compared to the predicate assay on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer. Contrived samples were made by spiking 25(OH) Vitamin D into individual samples to obtain Vitamin D levels at the high end of the Vitamin D assay measuring range. Results using Deming regression are summarized below:

<table><tr><td rowspan=1 colspan=1>Reagent Lot (y)</td><td rowspan=1 colspan=1>Reagent Lot 1</td><td rowspan=1 colspan=1>Reagent Lot 2</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>126</td></tr><tr><td rowspan=1 colspan=1>Range (ng/mL)</td><td rowspan=1 colspan=1>5.93 - 130.85</td><td rowspan=1 colspan=1>5.93 - 130.85</td></tr><tr><td rowspan=1 colspan=1>InterceptSlope</td><td rowspan=1 colspan=1>0.851.03</td><td rowspan=1 colspan=1>1.741.04</td></tr><tr><td rowspan=1 colspan=1>R Value</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99</td></tr></table>

# 2. Matrix Comparison:

To validate use of the ADVIA Centaur $\textsuperscript { \textregistered }$ VitD assay with different claimed sample types, the sponsor evaluated 66 native and 8 contrived matched sample sets (serum, serum separator tube, lithium heparin, sodium heparin, K2 EDTA, K3 EDTA) ranging in concentration from 13.0 to $1 4 2 . 9 \mathrm { n g / m L }$ . Samples were run along with calibrators and control on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer with one lot of reagent. All samples were tested in replicates of 3 and the first replicate was used to perform a Weighted-Deming fit regression analysis comparing all tube types to serum collected in a plain tube without a serum separator. Pearson correlation coefficient (R) was calculated and the results are summarized below:

<table><tr><td rowspan=1 colspan=1>Tube Type</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>Serum Separator</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>Sodium Heparin</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-1.13</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>-0.18</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>K2 EDTA</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>K3 EDTA</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>0.99</td></tr></table>

The results of this study support the use of the ADVIA Centaur $\textsuperscript { \textregistered }$ Vitamin D Total (VitD) assay with venous blood collected in serum tubes with or without a separator as well as plasma from venous blood collected in tubes with the following anticoagulants: sodium heparin, lithium heparin, $\mathrm { K } _ { 2 }$ EDTA, and $\mathrm { K } _ { 3 }$ EDTA.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

The sponsor performed a study referencing CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory to verify that the existing Reference Interval could be transferred to the modified Vitamin D assay. Twenty (20) samples from apparently healthy individuals were analyzed on one ADVIA Centaur $\textsuperscript { \textregistered }$ XP analyzer using one lot of the modified reagent. Results of the verification study and the performance studies support that the reference interval could be transferred to the modified reagent.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Adults</td><td rowspan=1 colspan=1>Pediatric(12 months up to 21 years)</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>22.5 ng/mL</td><td rowspan=1 colspan=1>23.8 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Observed Range2.5th to 97.5th Percentile</td><td rowspan=1 colspan=1>7.4 - 44.0 ng/mL</td><td rowspan=1 colspan=1>11.4 - 45.8 ng/mL</td></tr></table>

In addition, the labeling contains the following information on Vitamin D levels, and which is drawn from literature references:

<table><tr><td colspan="1" rowspan="1">Vitamin DStatus</td><td colspan="1" rowspan="1">Range, Adultng/mL (nmol/L)</td><td colspan="1" rowspan="1">Range, Pediatricng/mL (nmol/L)</td></tr><tr><td colspan="1" rowspan="1">Deficiency</td><td colspan="1" rowspan="1">&lt; 20 ng/mL (50 nmol/L)</td><td colspan="1" rowspan="1">&lt; 15 ng/mL (37.5 nmol/L)</td></tr><tr><td colspan="1" rowspan="1">Insufficiency</td><td colspan="1" rowspan="1">20− &lt; 30 ng/mL (50− &lt; 75 nmol/L)</td><td colspan="1" rowspan="1">15 − &lt; 20 ng/mL (37.5− &lt; 50 nmol/L)</td></tr><tr><td colspan="1" rowspan="1">Sufficiency</td><td colspan="1" rowspan="1">30100 ng/mL (75250 nmol/L)</td><td colspan="1" rowspan="1">20100 ng/mL (50250 nmol/L)</td></tr></table>

Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266–81.

Holick MF. MrOs is D-ficient. J Clin Endocrinol Metab. 2009;94(4):1092–3.

Rollins G. Vitamin D Testing–What’s the Right Answer? Labs Grapple with Confusing Analytics, Evidence. Clinical Laboratory News. July 2009;35(7): 1,6.

Freeman R. Vitamin D: The sunshine hormone. How and when to treat deficiencies.   
Menopausal Medicine. May 2009; S8–11.

Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. Pediatrics. 2008;122:398–417

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.